Epidyolex and Sativex approved but progress is very limited Epidyolex and Sativex and Sativex have both been approved for NHS prescription in England. Sativex, a mouth spray that contains a
The UK’s leading dementia research charity Alzheimer’s Research UK has announced it will fund a “pioneering” clinical trial at King’s College London using the “cannabis-based” treatment Sativex for people living
Jersey is often portrayed as a culturally backwards throwback to the 1950s but it has left mainland UK behind when it comes to legalising cannabis medicine after politicians there voted
With “cannabis-based” medicine becoming legal for specialist doctors to prescribe from 1 November, the Department for Health and Social Care has issued guidelines for specialists to follow. These products can
In the latest example that suggests specialist doctors are unlikely to make life any easier for UK patients seeking medicinal cannabis, Caroline Burns, a former council worker and mum who
New Scientist magazine has visited the GW Pharmaceuticals to interview Dr David Potter at the UK’s only legal cannabis farm, providing some revealing insights to the world of monopolised cannabis.
There are as many arguments as to leave or remain in the Union as there are people within the UK it seems… However here is one you likely haven’t considered
GW Pharmaceuticals; the company responsible for manufacturing Sativex, the cannabis extract in a spray bottle marketed for MS spasticity and neuropathic pain patients – have not tried to keep it
Sativex, the concentrated cannabis mouth spray, now has Schedule 4 status in England and Wales. This removes much of the red tape that is currently preventing medical professionals from prescribing
Sign up for our newsletter to get the latest news, plus exclusive access to our product launches!
